Uncategorized – Page 13

Novo Nordisk’s Amycretin Significantly Reduces Weight and Blood Sugar in Phase 2 Type 2 Diabetes Trial

3 weeks ago talkbio0Tagged Administration, Oral, Agonist, amycretin, Amylin Receptor Agonists, Diabetes Mellitus, Non-Insulin-Dependent, Glucagon-Like Peptide 1, Glycosylated hemoglobin A, Novo Nordisk, Phase 2 clinical trial, subcutaneous administration, Weight Loss

Novo Nordisk; Amycretin; Type 2 diabetes; Weight loss; HbA1c reduction; GLP-1 agonist; Amylin receptor agonist; Phase 2 clinical trial; Subcutaneous administration; Oral administration

FDA’s Pazdur Raises Concerns Over Legality of National Priority Voucher Program Amid Internal Disagreement

3 weeks ago talkbio0Tagged CNPV, Commissioner 's National Priority Voucher, Drug Approval Process, internal disagreement, legality, Pazdur, Tidmarsh, Tumor board, United States Food and Drug Administration

FDA; Pazdur; Commissioner’s National Priority Voucher; CNPV; legality; internal disagreement; tumor board; Tidmarsh; drug approval process

FDA Approves Novartis’ Itvisma: Expanding Gene Therapy to Older Spinal Muscular Atrophy Patients

3 weeks ago talkbio0Tagged Adult, Approved, gene therapy, intrathecal formulation, Itvisma, Novartis, older children, Spinal Muscular Atrophy, United States Food and Drug Administration, Zolgensma

Novartis; FDA approval; Itvisma; Zolgensma; Spinal Muscular Atrophy (SMA); Gene Therapy; Older Children; Adults; Intrathecal Formulation

ASH 2025: Breakthroughs in In Vivo CAR-T Data from Kelonia; Phase 3 Wins for Lilly, J&J, and Novartis

3 weeks ago talkbio0Tagged 2025, Asymmetric Septal Hypertrophy, CAR-T, CAR-T therapy, Eli Lilly, in vivo, Kelonia Therapeutics, Multiple Myeloma, Novartis, Phase 3 trials

ASH 2025; in vivo CAR-T; Kelonia Therapeutics; KLN-1010; multiple myeloma; Johnson & Johnson; Lilly; Novartis; CAR-T therapy; Phase 3 trials

Rakovina Therapeutics Showcases Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting

3 weeks ago talkbio0Tagged AI-discovered drugs, ATR, ATR/mTOR Inhibitors, Brain Neoplasms, CNS-penetrant, dual pathway inhibition, Enki generative AI, preclinical data, PTEN-deficient tumors, Rakovina, Society for Neuro-Oncology

Rakovina Therapeutics; AI-discovered drugs; CNS-penetrant; ATR/mTOR inhibitors; preclinical data; Society for Neuro-Oncology; brain cancer; PTEN-deficient tumors; Enki generative AI; dual pathway inhibition

Accelerating Breast Cancer Treatment Planning with Agentic AI: Recent Advances and Implementations (2025)

3 weeks ago talkbio0Tagged agentic AI, AI-guided, AWS HealthLake, Clinical Decision Support, DNA Integration, healthcare workflow, Malignant neoplasm of breast, Microsoft Teams, multi-agent systems, Neoplasms, Precision Medicine

agentic AI; breast cancer treatment; oncology; clinical decision support; multi-agent systems; healthcare workflow automation; personalized medicine; AWS HealthLake; Microsoft Teams integration; AI-guided treatment planning

White House Requests Resignation of Top FDA Aide, Prompting Tensions with Commissioner Makary

3 weeks ago talkbio0Tagged CHARGE Syndrome, controversy, internal tensions, management technique, Marty Makary, resignation, Sanjula Jain-Nagpal, United States Food and Drug Administration, White House, Workforce - population group

FDA; White House; Marty Makary; Sanjula Jain-Nagpal; resignation; HHS; staffing controversy; Robert F. Kennedy Jr.; management style; internal tensions

Novo Nordisk’s Semaglutide Misses Key Goals in Closely-Watched Alzheimer’s Disease Phase 3 Trials

3 weeks ago talkbio0Tagged Alzheimer 's disease, Biological Markers, Clinical trial failure, EVOKE trial, Glucagon-Like Peptide 1, Mental deterioration, Novo Nordisk, Phase 3, Rybelsus, semaglutide

Novo Nordisk; semaglutide; Alzheimer’s disease; EVOKE trial; EVOKE+ trial; clinical trial failure; Rybelsus; GLP-1 drugs; phase 3; biomarkers; cognitive decline